Evidence map›Paper›PMID 36788219›Full record

ArticleNPJ vaccines2023

Carbohydrate fatty acid monosulphate: oil-in-water adjuvant enhances SARS-CoV-2 RBD nanoparticle-induced immunogenicity and protection in mice.

Etsuro Nanishi, Francesco Borriello, Hyuk-Soo Seo, Timothy R O'Meara, Marisa E McGrath, Yoshine Saito, Jing Chen, Joann Diray-Arce, Kijun Song, Andrew Z Xu and 21 more

Erratum issuedOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in NPJ vaccines, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

31 authors at 8 institutions in 1 country.

Etsuro Nanishi *Precision Vaccines Program, Boston Children's Hospital, Boston, MA, USA.ORCID http://orcid.org/0000-0002-9957-7162
Francesco Borriello *Precision Vaccines Program, Boston Children's Hospital, Boston, MA, USA.
Hyuk-Soo SeoDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0003-0646-2102
Timothy R O'MearaPrecision Vaccines Program, Boston Children's Hospital, Boston, MA, USA.ORCID http://orcid.org/0000-0002-3651-5167
Marisa E McGrathDepartment of Microbiology and Immunology, Center for Pathogen Research, University of Maryland School of Medicine, Baltimore, MD, USA.
Yoshine SaitoPrecision Vaccines Program, Boston Children's Hospital, Boston, MA, USA.
Jing ChenResearch Computing Group, Boston Children's Hospital, Boston, MA, USA.
Joann Diray-ArcePrecision Vaccines Program, Boston Children's Hospital, Boston, MA, USA.
Kijun SongDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0002-6037-9345
Andrew Z XuDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0001-8576-9836
Soumik BarmanPrecision Vaccines Program, Boston Children's Hospital, Boston, MA, USA.ORCID http://orcid.org/0000-0002-3641-2125
Manisha MenonPrecision Vaccines Program, Boston Children's Hospital, Boston, MA, USA.
Danica DongPrecision Vaccines Program, Boston Children's Hospital, Boston, MA, USA.ORCID http://orcid.org/0000-0003-2180-6508
Timothy M CaradonnaRagon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA.
Jared FeldmanRagon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA.
Blake M HauserRagon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA.ORCID http://orcid.org/0000-0002-0100-1684
Aaron G SchmidtRagon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA.
Lindsey R BadenDepartment of Medicine, Brigham and Women's Hospital, Boston, MA, USA.
Robert K ErnstDepartment of Microbial Pathogenesis, University of Maryland School of Dentistry, Baltimore, MD, USA.ORCID http://orcid.org/0000-0001-5016-8694
Carly DillenDepartment of Microbiology and Immunology, Center for Pathogen Research, University of Maryland School of Medicine, Baltimore, MD, USA.
Jingyou YuCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
Aiquan ChangCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
Luuk HilgersLiteVax B.V, Oss, The Netherlands.
Peter Paul PlatenburgLiteVax B.V, Oss, The Netherlands.ORCID http://orcid.org/0000-0002-3419-1314
Sirano Dhe-PaganonDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.
Dan H BarouchCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0001-5127-4659
Al OzonoffPrecision Vaccines Program, Boston Children's Hospital, Boston, MA, USA.ORCID http://orcid.org/0000-0003-4233-5899
Ivan ZanoniDepartment of Pediatrics, Harvard Medical School, Boston, MA, USA.
Matthew B FriemanDepartment of Microbiology and Immunology, Center for Pathogen Research, University of Maryland School of Medicine, Baltimore, MD, USA.ORCID http://orcid.org/0000-0003-0107-0775
David J DowlingPrecision Vaccines Program, Boston Children's Hospital, Boston, MA, USA.ORCID http://orcid.org/0000-0003-1095-6156
Ofer LevyPrecision Vaccines Program, Boston Children's Hospital, Boston, MA, USA. ofer.levy@childrens.harvard.edu.ORCID http://orcid.org/0000-0002-5859-1945
Boston Children's Hospital · USUniversity of Maryland, Baltimore · USBeth Israel Deaconess Medical Center · USHarvard University · USRagon Institute of MGH, MIT and Harvard · USBroad Institute · USDana-Farber Cancer Institute · USBrigham and Women's Hospital · US

Funding

Medical Scientist Training ProgramT32GM144273 · NIGMS · HARVARD MEDICAL SCHOOL · PI David Shumway Jones, Jacqueline A. Lees · 2022 to 2026
$14.7M
Small-molecule adjuvants to enhance the efficacy of flu vaccines in newborns and the elderly75N93019C00044 · NIAID · BOSTON CHILDREN'S HOSPITAL · PI LEVY, OFER · 2019 to 2023
$11.0M
Development of a novel adjuvant strategy enabled by modulation of the physical properties of fungal mannansR01AI165505 · NIAID · BOSTON CHILDREN'S HOSPITAL · PI Ivan Zanoni · 2021 to 2026
$4.6M
NIAID NIH HHS 75N93019C00044NIAID NIH HHS HHSN272201400007CNIAID NIH HHS HHSN272201400052CNIAID NIH HHS HHSN272201800047CNIAID NIH HHS R01 AI165505NIGMS NIH HHS T32 GM144273
6 · The paper itself

Abstract

Development of SARS-CoV-2 vaccines that protect vulnerable populations is a public health priority. Here, we took a systematic and iterative approach by testing several adjuvants and SARS-CoV-2 antigens to identify a combination that elicits antibodies and protection in young and aged mice. While demonstrating superior immunogenicity to soluble receptor-binding domain (RBD), RBD displayed as a protein nanoparticle (RBD-NP) generated limited antibody responses. Comparison of multiple adjuvants including AddaVax, AddaS03, and AS01B in young and aged mice demonstrated that an oil-in-water emulsion containing carbohydrate fatty acid monosulphate derivative (CMS:O/W) most effectively enhanced RBD-NP-induced cross-neutralizing antibodies and protection across age groups. CMS:O/W enhanced antigen retention in the draining lymph node, induced injection site, and lymph node cytokines, with CMS inducing MyD88-dependent Th1 cytokine polarization. Furthermore, CMS and O/W synergistically induced chemokine production from human PBMCs. Overall, CMS:O/W adjuvant may enhance immunogenicity and protection of vulnerable populations against SARS-CoV-2 and other infectious pathogens.

Identifiers

PMID36788219
PMCPMC9927065
OpenAlexW4320725589

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.